https://www.taxtmi.com/news?id=51656 Intas Pharmaceuticals launched HETRONIFLY (serplulimab), the first PD 1 inhibitor approved for Extensive Stage Small Cell Lung Cancer in India under a licensing agreement; clinical support is drawn from the ASTRUM 005 trial showing mortality risk reduction and a high ESMO MCBS rating, with the drug described as employing dual PD L1/PD L2 blockade and strong PD 1 internalization. The launch emphasizes expanded market access, prior international approvals, and a substantially lower price relative to existing immunotherapies for this indication. en-us Wed, 06 Aug 2025 10:31:03 +0530 Wed, 06 Aug 2025 10:31:04 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=51656 Intas Pharmaceuticals launched HETRONIFLY (serplulimab), the first PD 1 inhibitor approved for Extensive Stage Small Cell Lung Cancer in India under a licensing agreement; clinical support is drawn from the ASTRUM 005 trial showing mortality risk reduction and a high ESMO MCBS rating, with the drug described as employing dual PD L1/PD L2 blockade and strong PD 1 internalization. The launch emphasizes expanded market access, prior international approvals, and a substantially lower price relative to existing immunotherapies for this indication. News - Wed, 06 Aug 2025 10:31:03 +0530 https://www.taxtmi.com/news?id=51656